Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 2/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5710568 | 0.85 | — | — | |
| SCHEMBL19379185 | 0.79 | PYCR1 (0.33) | PYCR1ALDH1A1KDM4EHPGD | |
| SCHEMBL8961259 | 0.79 | ALDH1A1 (0.42) | ALDH1A1HPGDLMNACYP1A2SMN1; SMN2 | |
| SCHEMBL537444 | 0.78 | CA12 (0.45) | ALDH1A1HPGD | |
| SCHEMBL5960264 | 0.76 | — | — | |
| SCHEMBL9423831 | 0.75 | KDM4E (0.31) | ALDH1A1KDM4EHPGDMAOBCYP1A2 | |
| SCHEMBL7200816 | 0.74 | PYCR1 (0.38) | PYCR1ALDH1A1KDM4EHPGDMAOB | |
| SCHEMBL27551745 | 0.74 | PYCR1 (0.31) | PYCR1 | |
| SCHEMBL7785447 | 0.74 | DPP4 (0.32) | PYCR1ALDH1A1TSHR | |
| SCHEMBL309219 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250174720-A1 | ELECTROLYTE, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | DAIKIN INDUSTRIES, LTD. (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| CN-115023267-A | Spirocyclic androgen receptor protein degrading agents | 密歇根大学董事会 | 2022-09-06 | — | — | CN | disclosed |
| EP-4021580-A1 | CEREBLON E3 LIGASE INHIBITORS | The Regents Of The University Of Michigan (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3902533-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | Forma Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| WO-2021055668-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021041664-A1 | CEREBLON E3 LIGASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2020191022-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020139916-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| EP-3252050-B1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| US-9926282-B2 | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-27 | — | — | US | disclosed |
| EP-3252049-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3252050-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2073804-B1 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ASTEX THERAPEUTICS LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-10 | — | — | US | disclosed |
| EP-2945943-A2 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014113620-A2 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-24 | — | — | WO | disclosed |
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| EP-1885713-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006123242-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | PYCR1 1016/4885LIMK1 3797/4885LIMK2 4160/4885 |
| US-20080234252-A1 | Compounds Useful in Therapy | AVPR1A, AVPR1B, AVPR2 | PYCR1 2748/4885LIMK1 3884/4885LIMK2 3974/4885 |
| US-20250174720-A1 | ELECTROLYTE, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | HCN2, HCN1, HCN3 | PYCR1 3677/4885LIMK1 1120/4885LIMK2 1514/4885 |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | PYCR1 1209/4885LIMK1 245/4885LIMK2 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.